Insight

Aref Al-Kali: AML is hanging with use of FLT3i and Allo BMT

Photo of Aref Al-Kali from mayoclinic.org

Jul 8, 2024, 16:34

Aref Al-Kali: AML is hanging with use of FLT3i and Allo BMT

Aref Al-Kali, Hematologist/Oncologist at Mayo Clinic, shared on X:

“Outcome of t6;9 AML changing with use of FLT3i and Allo BMT. Plan for larger multisite study lead by Clifford Csizmar.

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214).”

Source: Aref Al-Kali/X

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience

Authors: Clifford M Csizmar, Antoine N Saliba, Patricia T Greipp, Hassan Alkhateeb, Kebede H Begna, James M Foran, Naseema Gangat, William J Hogan, C Christopher Hook, Mark R Litzow, Abhishek A Mangaonkar, Jeanne M Palmer, Animesh Pardanani, Mithun V Shah, Ayalew Tefferi, Mehrdad Hefazi Torghabeh, Alexandra P Wolanskyj-Spinner, Mrinal M Patnaik, Scott H Kaufmann, Aref Al-Kali

Abhishek A Mangaonkar Alexandra P Wolanskyj-Spinner AML Animesh Pardanani Antoine N Saliba Aref Al-Kali Ayalew Tefferi BMT C Christopher Hook cancer Clifford Csizmar Clifford M Csizmar FLT3i Hassan Alkhateeb James M Foran Jeanne M Palmer Kebede H Begna Mark R Litzow Mayo Clinic Mehrdad Hefazi Torghabeh Mithun V Shah Mrinal M Patnaik Naseema Gangat OncoDaily Oncology Patricia T Greipp Scott H Kaufmann William J Hogan

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage